The NanoV  Therapeutics LLC

- A cure for incurables -

We provide a class of the first-of-its kind anti-tumoral agents to cancer patients

 

About Us

Petri Dish

  NanoV Therapeutics LLC aims to provide a class of the first-of-its kind anti-tumoral agents to cancer patients. Our company was launched on March 2018. Our team is made up of scientists and professors with profound expertise in cancer medicine.

  Our discovery of the groundbreaking drugs was filed with patent applications through Emory University on April 2018.


We are currently going through Georgia Research Alliance venture grant (Phase IA&IB) to support the translation of the exciting bench discovery to clinics. We are now preparing to reach the one-to-one matching fund Phase II.


We extensively work to secure more grants including recently submitted NIH STTR grant application on January 2019 to facilitate our business in drug development.